Eyad Hijazin, MD
Internal Medicine · Mamaroneck, NYNPI 1356320410
Payments from drug & device makers
Across 153 payments — averaging $59.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Novo Nordisk$504
- Merz North America, Inc.$364
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$337
- Galderma Laboratories, L.p.$320
- Novartis$275
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$5,15056%
- Food & beverage$3,98644%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $5,037 |
| Novo Nordisk | 22 | $504 |
| Merz North America, Inc. | 2 | $364 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $337 |
| Galderma Laboratories, L.p. | 5 | $320 |
| Novartis | 15 | $275 |
| Pfizer | 12 | $231 |
| Vanda Pharmaceuticals Inc. | 11 | $229 |
| AstraZeneca | 7 | $227 |
| Qiagen, LLC | 2 | $189 |
| Shield Therapeutics Inc | 3 | $162 |
| Amgen(2 entities) | 8 | $148 |
| Exact Sciences | 6 | $136 |
| Boehringer Ingelheim | 6 | $131 |
| Biohaven Pharmaceuticals, Inc. | 2 | $114 |
| Bayer | 6 | $109 |
| GSK | 4 | $109 |
| Abbott | 3 | $51 |
| Lilly USA, LLC | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $42 |
| Alk-abello, Inc | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Mannkind Corporation | 2 | $29 |
| Johnson & Johnson | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Verona Pharma, Inc. | 1 | $25 |
| Livanova USA, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Merck | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Acelrx Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$364
- MDX QUANTIFERON$177
- CAPLYTA$125
- FARXIGA$125
- Wegovy$125
How this compares
$9,136 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 200 | $144,546 |
| JanuviaSitagliptin Phosphate | 100 | $78,861 |
| JardianceEmpagliflozin | 82 | $78,662 |
| XeljanzTofacitinib Citrate | 12 | $71,658 |
| OzempicSemaglutide | 60 | $63,168 |
| RybelsusSemaglutide | 33 | $41,870 |
| TrulicityDulaglutide | 36 | $36,741 |
| FarxigaDapagliflozin Propanediol | 50 | $33,328 |
| XareltoRivaroxaban | 27 | $25,083 |
| EntrestoSacubitril/Valsartan | 30 | $21,113 |
| TradjentaLinagliptin | 20 | $12,760 |
| Spiriva HandihalerTiotropium Bromide | 23 | $12,467 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $12,082 |
| MyrbetriqMirabegron | 17 | $11,700 |
| PennsaidDiclofenac Sodium | 11 | $11,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Xeljanz | $231 | $216,204212 claims |
| Novo NordiskOzempic, Rybelsus | $504 | $105,03893 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $131 | $97,555114 claims |
| MerckJanuvia | $19 | $78,861100 claims |
| AstraZenecaFarxiga, Symbicort | $227 | $38,04069 claims |
| Lilly USA, LLCTrulicity | $44 | $36,74136 claims |
| Johnson & JohnsonXarelto | $28 | $25,08327 claims |
| NovartisEntresto | $275 | $21,11330 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $109 | $20,04039 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $11,70017 claims |
| AmgenPennsaid | $148 | $11,58811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Mamaroneck
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.